Acucela to Present at BIO International Convention.BOTHELL, Wash. -- Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for blinding eye diseases, today announced that Ryo Kubota, M.D., Ph.D., Acucela's chief executive officer, will present next week at the BIO Business Forum during the 2008 BIO International Convention to be held in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. from June 17-20. Dr. Kubota will present at 2:00 p.m. PT on June 17th in room 5A, and will provide the audience with an overview of Acucela and its activities including its recently initiated clinical trial for age-related macular degeneration Age-related macular degeneration (ARMD) Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60. . "The BIO International Convention provides an excellent venue for us to talk about Acucela to many different audiences and to discuss the encouraging data that we have observed to date in our programs for multiple blinding eye diseases, including our clinical-stage program for age-related macular degeneration," stated Dr. Kubota. "Our mission is to develop therapies which prevent blindness, so we are working to develop safer, more efficacious ef·fi·ca·cious adj. Producing or capable of producing a desired effect. See Synonyms at effective. [From Latin effic therapies for multiple eye diseases that target large unmet needs." About Acucela Acucela Inc. is focused on developing new drug therapies for eye diseases, and particularly neurodegenerative retinal retinal /ret·i·nal/ (ret´i-n'l) 1. pertaining to the retina. 2. the aldehyde of retinol, derived from absorbed dietary carotenoids or esters of retinol and having vitamin A activity. diseases such as macular degeneration macular degeneration, eye disorder causing loss of central vision. The affected area, the macula, lies at the back of the retina and is the part that produces the sharpest vision. . The company has proprietary disease-specific assays and technologies to identify and develop compounds that may safely and effectively treat retinal diseases. The company's novel approaches have significant therapeutic potential to treat retinal diseases such as Age-related Macular Degeneration (AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. ) and Stargardt disease. The Bothell-based, privately-held, biotechnology company was founded in 2002. For more information, please visit http://www.acucela.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion